Bausch + Lomb’s New Board Agreements Announced

Bausch + Lomb Corporation ( (BLCO) ) has shared an update.

On May 19, 2025, Bausch Health Companies Inc., the majority shareholder of Bausch + Lomb Corporation, entered into letter agreements with the Icahn Group, Paulson Group, and Kavanagh Group. These agreements stipulate that if any of these groups engage in specified actions, they must resign from the boards of both Bausch Health and Bausch + Lomb. The agreements also include provisions for voting on board nominees, aiming to maintain stability in board representation.

The most recent analyst rating on (BLCO) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.

Spark’s Take on BLCO Stock

According to Spark, TipRanks’ AI Analyst, BLCO is a Neutral.

Bausch + Lomb’s overall score reflects solid revenue growth and a strong gross margin, but significant challenges in profitability and cash flow. Technical analysis shows bearish trends, while valuation metrics indicate poor earnings performance. The earnings call provided some optimism with growth in key segments, though risks remain from Pharmaceuticals and tariff pressures.

To see Spark’s full report on BLCO stock, click here.

More about Bausch + Lomb Corporation

Bausch + Lomb Corporation operates in the healthcare industry, focusing primarily on eye health products including contact lenses, lens care products, and ophthalmic pharmaceuticals.

Average Trading Volume: 856,662

Technical Sentiment Signal: Sell

Current Market Cap: $4.16B

For a thorough assessment of BLCO stock, go to TipRanks’ Stock Analysis page.